Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Sylvant | — | 2014-05-22 | europa.eu ↗ |
| Approved | US (FDA) | SYLVANT | — | 2014-04-23 | fda.gov ↗ |
Trials 36 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02796859 Comparator | May 2016 → Dec 2023 | schizophrenia | Brian Miller | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07709000 Background | Aug 2026 → Nov 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04838860 Comparator | Mar → Apr 2021 | idiopathic multicentric Castleman disease | RECORDATI GROUP | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07570173 Background | May 2026 → Oct 2033 expected | B-cell acute lymphoblastic leukemia | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04330638 Comparator | Apr → Dec 2020 | COVID-19 | University Hospital, Ghent | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 43 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | siltuximab | “Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with...” PMID 20484019 ↗ May 201035“Siltuximab is a monoclonal antibody that blocks interleukin-6 (IL-6) from binding to its receptor, preventing it from acting.” NCT06447376 ↗ “A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors” NCT00841191 ↗ |
| Known as | CLLB8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743070 ↗ |
| Known as | CNTO328 | “Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with...” PMID 20484019 ↗ May 201010“A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors” NCT00841191 ↗ “This is a research study with an experimental drug called siltuximab (also known as CNTO 328).” NCT01219010 ↗ “This is a research study with an experimental drug called siltuximab (also known as CNTO 328).” NCT01266811 ↗ “A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma” NCT01309412 ↗ |
| Known as | Sylvant | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743070 ↗ |
| Action | Inhibit | “anti-IL-6 monoclonal antibody” NCT00265135 ↗ |
| Modality | Monoclonal antibody | “anti-IL-6 monoclonal antibody” NCT00265135 ↗ |
| Route | Intravenous | “4 intravenous infusions (IV)” NCT00265135 ↗ |
| Target | IL6 | “anti-IL-6 monoclonal antibody” NCT00265135 ↗ |